Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
Cardiff Oncology reported that its Phase 2 trial remains ongoing. Median PFS has not been reached in the 30 mg onvansertib plus FOLFIRI/bev arm, compared with approximately 11 months in the combined SoC arms.
Why it matters — The update provides CRDF watchers with a comparison of median PFS in the ongoing trial’s treatment and standard-of-care arms.